Submissions for OMB Review; Comment Request; Evaluation of the Impact of the New Conflicts of Interest Regulations on the National Institutes of Health's Ability to Recruit and Retain Staff, 10768-10769 [07-1087]
Download as PDF
10768
Federal Register / Vol. 72, No. 46 / Friday, March 9, 2007 / Notices
III. Paperwork Reduction Act of 1995
This guidance refers to previously
approved collections of information
found in Guidance for Industry #170.
These collections of information are
subject to review by the Office of
Management and Budget under the
Paperwork Reduction Act of 1995 (44
U.S.C. 3501–3520) and have been
approved under OMB Control No. 0910–
0540.
IV. Comments
Interested persons may, at any time,
submit to the Division of Dockets
Management (see ADDRESSES) written or
electronic comments regarding the
guidance. Submit a single copy of
electronic comments or two paper
copies of any mailed comments, except
that individuals may submit one paper
copy. Comments are to be identified
with the docket number found in the
brackets in the heading of this
document. A copy of the guidance and
received comments are available for
public examination in the Division of
Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday.
V. Electronic Access
Persons with access to the Internet
may obtain the guidance at either CVM
home page (https://www.fda.gov/cvm) or
the Division of Dockets Management
Web site https://www.fda.gov/ohrms/
dockets/default.htm.
Dated: March 1, 2007.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E7–4322 Filed 3–8–07; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Submissions for OMB Review;
Comment Request; Evaluation of the
Impact of the New Conflicts of Interest
Regulations on the National Institutes
of Health’s Ability to Recruit and
Retain Staff
Summary: Under the provisions of
Section 3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, the Office of
Human Resources (OHR), the National
Institutes of Health (NIH) has submitted
to the Office of Management and Budget
(OMB) a request for review and
approval of the information collection
listed below. The purpose of this notice
is to allow 30 days for public comment.
The NIH may not conduct or sponsor,
and the respondent is not required to
respond to, an information collection
that has been extended, revised, or
implemented on or after October 1,
1995, unless it displays a currently valid
OMB control number.
Proposed Collection
Title: Evaluation of the Impact of the
New Conflicts of Interest regulations on
the National Institutes of Health’s
Ability To Recruit and Retain Staff.
Type of Information Collection
Request: NEW.
Need and Use of Information
Collection: To assess the impact of new
Department of Health and Human
Services (HHS) conflicts of interest
regulations on the NIH’s ability to
continue to attract and recruit highly
qualified scientific personnel. Gauging
both the immediate and long-term
impact of these new rules is crucial to
Number of respondents
Type of respondent
jlentini on PROD1PC65 with NOTICES
Potential Applicants .........................................................................................
Former NIH Employees ...................................................................................
TOTAL ......................................................................................................
Total Number of Respondents: 500.
Total Number of Responses: 500.
Total Hours: 116.67 hours.
The annualized cost to respondents is
estimated at: $3,850.
There are no capital costs, operating
costs, and/or maintenance costs to
report.
Request for Comments: Written
comments and/or suggestions from the
public and affected agencies are invited
on one or more of the following points:
(1) Whether the proposed collection of
VerDate Aug<31>2005
21:24 Mar 08, 2007
Jkt 211001
400
100
500
information is necessary for the proper
performance of the function of the
agency, including whether the
information will have practical utility;
(2) The accuracy of the agency’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) Ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
Ways to minimize the burden of the
collection of information on those who
PO 00000
Frm 00139
Fmt 4703
Sfmt 4703
NIH’s ability to develop and maintain a
world-class staff. This project will
produce data that will help NIH and
HHS leaders determine the impact of
the regulations and how to minimize the
effect of the regulations on NIH’s ability
to recruit and retain staff. NIH intends
to survey potential applications for NIH
employment from scientific
organizations from which NIH has
traditionally drawn leading scientific
personnel, and those senior scientists
and administrators who have
voluntarily left NIH since February
2005. This will allow NIH to determine
whether the regulations impact
individuals’ attitudes about
employment at NIH and the likelihood
of their joining and/or leaving the
agency. This proposed one-time survey
is part of a larger study that will provide
OHR with the high-quality data needed
to evaluate the impact of the new rules.
Data will be collected on respondents’
understanding of the new regulations,
how they believe the regulations could
impact them, and on their feelings about
working at NIH in light of the
regulations. Data will also be collected
from current NIH employees and the
combined data will be used in the
review of the rules. The survey is
planned to launch in early 2007 and to
be in the field for eight weeks.
Frequency of Response: Once.
Affected Public: Individuals or
households.
Type of Respondents: Potential
applicants for NIH positions and senior
scientists and administrators who have
voluntarily left NIH since February
2005.
The annual reporting burden is as
follows:
Frequency of
response
Average time
per response
(minutes)
1
1
........................
15
10
........................
Estimated total
annual hour
burden
(hours)
100
16.67
116.67
are to respond, including the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms of
information technology.
Direct Comment to OMB: Written
comments and/or suggestions regarding
the item(s) contained in this notice,
especially regarding the estimated
public burden and associated response
time, should be directed to the: Office
of Management and Budget, Office of
Regulatory Affairs, New Executive
E:\FR\FM\09MRN1.SGM
09MRN1
Federal Register / Vol. 72, No. 46 / Friday, March 9, 2007 / Notices
Office Building, Room 10235,
Washington, DC 20503, Attention: Desk
Officer for NIH. To request more
information on the proposed project or
to obtain a copy of the data collection
plans and instruments, contact Mr.
Richard M. Taffet, Director, Client
Services Division; Office of Human
Resources, Office of the Director,
National Institutes of Health, Room 2–
D234, East Jefferson Street, Bethesda,
MD 20892–8503, or call the non-toll-free
number 301–402–6627, or e-mail your
comments or request, including your
address, to: Taffetr@mail.nih.gov.
Comments Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 30 days of this
publication.
Dated: February 26, 2007.
Richard M. Taffet,
Director, Client Services Division, OHR, OD,
National Institutes of Health.
[FR Doc. 07–1087 Filed 3–8–07; 8:45 am]
BILLING CODE 4140–10–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
AGENCY:
ACTION:
Notice.
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
jlentini on PROD1PC65 with NOTICES
ADDRESSES:
VerDate Aug<31>2005
21:24 Mar 08, 2007
Jkt 211001
Methods of Treating Conditions
Characterized by Unwanted or
Excessive Presynaptic Neuronal
Activity or Secretion
Description of Technology: Botulinum
toxins are highly potent neurotoxins
produced by the spore-forming
bacterium, Clostridium botulinum.
Poisoning by any of the seven known
botulinum toxin serotypes, designated A
to G, results in impaired communication
between nerve and muscle that causes
paralysis in patients and possible death
by respiratory failure. Injections of
botulinum toxins A and B have been
approved for treating disorders
associated with uncontrollable muscle
contractions. However, the use of
approved botulinum toxins is limited by
their temporary duration of action, the
development of neutralizing antibodies
after repeated injections, and crossreactivity with autonomic neurons.
Thus, an interest exists in finding new
ways to achieve longer-lasting effects
using botulinum toxins.
This technology describes a novel
method for treating diseases by
combining two botulinum toxins,
botulinum toxin A and B. Researchers at
the FDA have shown that the
combination of the A and B toxins is
synergistic, improves muscle paralysis
characteristics compared to individually
administered serotypes, and produces a
longer duration of action and a faster
onset of paralysis. The synergistic effect
allows lower doses compared to single
use of either toxin and should help
reduce resistance after repeated use.
This technology is beneficial for the
treatment of diseases already known to
be treatable with botulinum toxins, such
as facial wrinkles, headaches, muscle
spasms, and cervical dystonia. This
technology is also suitable to treat other
diseases, such as strabismus, hemifacial
spasms, facial nerve damage, and
hyperhidrosis (excessive sweating).
Available for licensing are methods
and pharmaceutical compositions for
administering a combination of
botulinum toxin A and B to treat
unwanted or excessive presynaptic
neuronal activity or secretion.
Application: Alternative therapy for
diseases treatable with individual
botulinum toxins; such therapies
include Botox, Botox Cosmetic, and
Myobloc.
Market: Patients who are currently
prescribed individual toxins for
treatment of diseases such as
strabismus, blepharospasm, cervical
dystonia, and cosmetic wrinkle
reduction.
Development Status: Pre-clinical data
is available.
PO 00000
Frm 00140
Fmt 4703
Sfmt 4703
10769
Inventors: James E. Keller (CBER/
FDA).
Publications: JE Keller. Recovery from
botulinum neurotoxin poisoning in
vivo. Neuroscience 2006 May
12;139(2):629–637.
Patent Status: U.S. Provisional
Application No. 60/773,412 filed 15 Feb
2006 (HHS Reference No. E–172–2005/
0–US–01).
Licensing Status: Available for
exclusive or non-exclusive licensing.
Licensing Contact: Norbert Pontzer,
PhD, J.D.; 301/435–5502;
pontzern@mail.nih.gov.
Collaborative Research Opportunity:
The FDA Center for Biologics
Evaluation and Research, Laboratory of
Respiratory and Special Pathogens, is
seeking statements of capability or
interest from parties interested in
collaborative research to further
develop, evaluate, or commercialize this
technology. Please contact James E.
Keller, PhD, at 301/ for more
information.
Synergistic Effect of TGF-Beta Blockade
and Immunogenic Agents on Tumors
Description of Technology:
Overcoming immune suppression in
cancer patients is a major challenge for
the success of cancer immunotherapy.
TGF–b and its receptors are expressed
in essentially all tissues, and they have
been found to be important in many
cellular processes including cell growth
inhibition. The inhibition of TGF–b
signaling has been shown to have an
inhibitory effect on tumor growth.
However, TGF–b also has
immunosuppressive properties.
Cancer vaccines are one of many
therapies available for treatment and
prevention. In particular, vaccines that
elicit immune responses have been used
to treat or control tumor growth that has
evaded immunosurveillance. However,
these vaccines have demonstrated
limited success.
Available for licensing is a method for
synergistically affecting tumor growth
involving the administration of an agent
that blocks the TGF–b signaling
pathway, in combination with an
immunogenic agent. The agent that
blocks the TGF–b signaling pathway
may inhibit the immunosuppressive
effects of TGF–b, while the
immunogenic agent is believed to
enhance an immune response.
Surprisingly, the combination of such
elements produces a synergistic effect.
The administration of the 1D11.16 antiTGF–b antibody in combination with
the human papilloma virus E7(49–57)
peptide enhances tumor regression in an
animal model. The administration of the
1D11.16 anti-TGF–b antibody in
E:\FR\FM\09MRN1.SGM
09MRN1
Agencies
[Federal Register Volume 72, Number 46 (Friday, March 9, 2007)]
[Notices]
[Pages 10768-10769]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 07-1087]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Submissions for OMB Review; Comment Request; Evaluation of the
Impact of the New Conflicts of Interest Regulations on the National
Institutes of Health's Ability to Recruit and Retain Staff
Summary: Under the provisions of Section 3507(a)(1)(D) of the
Paperwork Reduction Act of 1995, the Office of Human Resources (OHR),
the National Institutes of Health (NIH) has submitted to the Office of
Management and Budget (OMB) a request for review and approval of the
information collection listed below. The purpose of this notice is to
allow 30 days for public comment. The NIH may not conduct or sponsor,
and the respondent is not required to respond to, an information
collection that has been extended, revised, or implemented on or after
October 1, 1995, unless it displays a currently valid OMB control
number.
Proposed Collection
Title: Evaluation of the Impact of the New Conflicts of Interest
regulations on the National Institutes of Health's Ability To Recruit
and Retain Staff.
Type of Information Collection Request: NEW.
Need and Use of Information Collection: To assess the impact of new
Department of Health and Human Services (HHS) conflicts of interest
regulations on the NIH's ability to continue to attract and recruit
highly qualified scientific personnel. Gauging both the immediate and
long-term impact of these new rules is crucial to NIH's ability to
develop and maintain a world-class staff. This project will produce
data that will help NIH and HHS leaders determine the impact of the
regulations and how to minimize the effect of the regulations on NIH's
ability to recruit and retain staff. NIH intends to survey potential
applications for NIH employment from scientific organizations from
which NIH has traditionally drawn leading scientific personnel, and
those senior scientists and administrators who have voluntarily left
NIH since February 2005. This will allow NIH to determine whether the
regulations impact individuals' attitudes about employment at NIH and
the likelihood of their joining and/or leaving the agency. This
proposed one-time survey is part of a larger study that will provide
OHR with the high-quality data needed to evaluate the impact of the new
rules. Data will be collected on respondents' understanding of the new
regulations, how they believe the regulations could impact them, and on
their feelings about working at NIH in light of the regulations. Data
will also be collected from current NIH employees and the combined data
will be used in the review of the rules. The survey is planned to
launch in early 2007 and to be in the field for eight weeks.
Frequency of Response: Once.
Affected Public: Individuals or households.
Type of Respondents: Potential applicants for NIH positions and
senior scientists and administrators who have voluntarily left NIH
since February 2005.
The annual reporting burden is as follows:
----------------------------------------------------------------------------------------------------------------
Estimated
Number of Frequency of Average time total annual
Type of respondent respondents response per response hour burden
(minutes) (hours)
----------------------------------------------------------------------------------------------------------------
Potential Applicants............................ 400 1 15 100
Former NIH Employees............................ 100 1 10 16.67
TOTAL....................................... 500 .............. .............. 116.67
----------------------------------------------------------------------------------------------------------------
Total Number of Respondents: 500.
Total Number of Responses: 500.
Total Hours: 116.67 hours.
The annualized cost to respondents is estimated at: $3,850.
There are no capital costs, operating costs, and/or maintenance
costs to report.
Request for Comments: Written comments and/or suggestions from the
public and affected agencies are invited on one or more of the
following points: (1) Whether the proposed collection of information is
necessary for the proper performance of the function of the agency,
including whether the information will have practical utility; (2) The
accuracy of the agency's estimate of the burden of the proposed
collection of information, including the validity of the methodology
and assumptions used; (3) Ways to enhance the quality, utility, and
clarity of the information to be collected; and (4) Ways to minimize
the burden of the collection of information on those who are to
respond, including the use of appropriate automated, electronic,
mechanical, or other technological collection techniques or other forms
of information technology.
Direct Comment to OMB: Written comments and/or suggestions
regarding the item(s) contained in this notice, especially regarding
the estimated public burden and associated response time, should be
directed to the: Office of Management and Budget, Office of Regulatory
Affairs, New Executive
[[Page 10769]]
Office Building, Room 10235, Washington, DC 20503, Attention: Desk
Officer for NIH. To request more information on the proposed project or
to obtain a copy of the data collection plans and instruments, contact
Mr. Richard M. Taffet, Director, Client Services Division; Office of
Human Resources, Office of the Director, National Institutes of Health,
Room 2-D234, East Jefferson Street, Bethesda, MD 20892-8503, or call
the non-toll-free number 301-402-6627, or e-mail your comments or
request, including your address, to: Taffetr@mail.nih.gov.
Comments Due Date: Comments regarding this information collection
are best assured of having their full effect if received within 30 days
of this publication.
Dated: February 26, 2007.
Richard M. Taffet,
Director, Client Services Division, OHR, OD, National Institutes of
Health.
[FR Doc. 07-1087 Filed 3-8-07; 8:45 am]
BILLING CODE 4140-10-M